About Concerto Biosciences
Concerto Biosciences is a company based in Cambridge (United States) founded in 2019 by Bernardo Cervantes and Jared Kehe.. Concerto Biosciences has raised $24.54 million across 2 funding rounds from investors including HHS, Safar Partners and Horizons Ventures. Concerto Biosciences offers products and services including ENS-002, CB-002, and ENS-003. Concerto Biosciences operates in a competitive market with competitors including ASLAN Pharmaceuticals, UNION Therapeutics, Biosion, Forte Biosciences and PinCell, among others.
- Headquarter Cambridge, United States
- Founders Bernardo Cervantes, Jared Kehe
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Concerto Biosciences
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$24.54 M (USD)
in 2 rounds
-
Latest Funding Round
$299.91 K (USD), Grant
Jul 01, 2022
-
Investors
HHS
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Concerto Biosciences
Concerto Biosciences offers a comprehensive portfolio of products and services, including ENS-002, CB-002, and ENS-003. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Microbiome-based treatment for atopic dermatitis conditions.
Product for achieving calm and balanced skin health.
Microbiome solution for vaginal yeast infection management.
Unlock access to complete
Unlock access to complete
Funding Insights of Concerto Biosciences
Concerto Biosciences has successfully raised a total of $24.54M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $299.91 thousand completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $299,907
-
First Round
First Round
(15 Jun 2022)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2022 | Amount | Grant - Concerto Biosciences | Valuation |
investors |
|
| Jun, 2022 | Amount | Series A - Concerto Biosciences | Valuation | Safar Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Concerto Biosciences
Concerto Biosciences has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Safar Partners and Horizons Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Safar Partners is engaged in investing in technology startups.
|
Founded Year | Domain | Location | |
|
Horizons Ventures is focused on investing in deep science and technology.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Concerto Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Concerto Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Concerto Biosciences Comparisons
Competitors of Concerto Biosciences
Concerto Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ASLAN Pharmaceuticals, UNION Therapeutics, Biosion, Forte Biosciences and PinCell, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted small molecules are developed for oncology treatments.
|
|
| domain | founded_year | HQ Location |
Small molecule antibiotics are developed for bacterial infections.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of anti-inflammatory therapy for the treatment skin diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Concerto Biosciences
Frequently Asked Questions about Concerto Biosciences
When was Concerto Biosciences founded?
Concerto Biosciences was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Where is Concerto Biosciences located?
Concerto Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Concerto Biosciences a funded company?
Concerto Biosciences is a funded company, having raised a total of $24.54M across 2 funding rounds to date. The company's 1st funding round was a Series A of $24.54M, raised on Jun 15, 2022.
What does Concerto Biosciences do?
Founded in 2019 and based in Cambridge, United States, Concerto Biosciences operates in the biotechnology sector. Microbe-based solutions are created for applications in agriculture and human health. A lead product, ENS-002, is offered, consisting of microbes that restore skin microbiome balance and reduce S. aureus virulence to address eczema. Operations focus on rehabilitating protective microbial interactions.
Who are the top competitors of Concerto Biosciences?
Concerto Biosciences's top competitors include ASLAN Pharmaceuticals, UNION Therapeutics and Biosion.
What products or services does Concerto Biosciences offer?
Concerto Biosciences offers ENS-002, CB-002, and ENS-003.
Who are Concerto Biosciences's investors?
Concerto Biosciences has 5 investors. Key investors include HHS, Safar Partners, Horizons Ventures, M-Ventures, and Corundum Systems Biology.